Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803491 | 1.00 | PPARA (0.47) | PPARAPPARGNPC1ACEMAPK14 | |
| SCHEMBL5803489 | 1.00 | PPARA (0.47) | PPARAPPARGNPC1ACEMAPK14 | |
| SCHEMBL5802884 | 0.95 | PPARG (0.49) | PPARAPPARGACEMAPK14PPARD | |
| SCHEMBL5802875 | 0.95 | PPARG (0.49) | PPARAPPARGACEMAPK14PPARD | |
| SCHEMBL5802879 | 0.95 | PPARG (0.49) | PPARAPPARGACEMAPK14PPARD | |
| SCHEMBL5803574 | 0.94 | PPARA (0.48) | PPARAPPARGNPC1ACEPPARD | |
| SCHEMBL5803576 | 0.94 | PPARA (0.48) | PPARAPPARGNPC1ACEPPARD | |
| SCHEMBL5803572 | 0.94 | PPARA (0.48) | PPARAPPARGNPC1ACEPPARD | |
| SCHEMBL5805185 | 0.93 | LMNA (0.45) | PPARAPPARGNPC1ACEMAPK14 | |
| SCHEMBL5805184 | 0.93 | LMNA (0.45) | PPARAPPARGNPC1ACEMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006083266-A1 | INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | WO | disclosed |
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | PSMB3, GBA3, PSMG3 | PPARA 4474/4885PPARG 4386/4885NPC1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.